Physician profile
David A Brenner
NPI 1679649024
$48,563.77
in general payments reported to CMS, 2019-2025
7 companies · $2,429 in 2025
The $2,429 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $2,100 · 2021: $4,759 · 2022: $12K · 2024: $4,800 · 2025: $2,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,900 · Travel and Lodging: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,900.00 |
| Travel and Lodging | $329.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22,407.41 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $12,232.00 | 2019 | |
| Gilead Sciences, INC. | $7,229.19 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,175.00 | 2019 | |
| Glaxosmithkline, LLC. | $2,659.43 | 2021 | |
| Otsuka Pharmaceutical Co., LTD. | $755.69 | 2019 | |
| Konica Minolta Healthcare Americas, INC | $105.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.